Overview and Specific Aims. The development of research and physician scientists into productive independent translational investigators is one of the most important goals of the principal investigators, the SPORE, the University of Pittsburgh Cancer Institute (UPCI) and the Institution. To accomplish this, the Career Development Program of the University of Pittsburgh Skin Cancer SPORE will pursue the following Specific Aims: 1. To identify and attract research and physician scientists with demonstrated outstanding potential, to develop an independent career in translational research in the area of cutaneous oncology. 2. To provide such research and physician scientists with mentoring, financial support, and a productive stimulating environment, during the formative stages of their careers, to facilitate their development into productive translational investigators. We intend the SPORE Career Development to complement existing award mechanisms designed to address these issues, including recently implemented NIH sponsored debt forgiveness programs. Furthermore, we anticipate that this SPORE Career Development Program will facilitate development of a successful T32 training grant application focused on Cutaneous Oncology. To accomplish these goals, we are not requesting support through the SPORE mechanism, because we would prefer to direct SPORE funds to the translational research projects proposed. Instead, we will utilize $50,000 of committed funds from the UPCI. This resource will be used to fund one Career Development award of $50,000 per year. Awards will be for an initial 1-year period, with the possibility for competitive renewal for a second year. Awardees will be required to devote at least 80% effort overall to translational research. Less than 80% salary support may be requested through this mechanism, enabling trainees to leverage other competitive and institutional sources of research support when appropriate (while maintaining at least 80% effort in translational research)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-05
Application #
8379337
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$113,424
Indirect Cost
$42,008
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Retseck, Janet; VanderWeele, Robert; Lin, Hui-Min et al. (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 4:38
Scharping, Nicole E; Menk, Ashley V; Moreci, Rebecca S et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45:374-88
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Bengsch, Bertram; Johnson, Andy L; Kurachi, Makoto et al. (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358-73
Sottile, Rosa; Pangigadde, Pradeepa N; Tan, Thomas et al. (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46:409-19
Fan, Yiping; Lee, Seungjae; Wu, Gang et al. (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136:339-42
Davar, Diwakar; Kirkwood, John M (2016) Adjuvant Therapy of Melanoma. Cancer Treat Res 167:181-208
Butterfield, Lisa H (2016) Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 65:805-12
Zarour, Hassane M (2016) Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res 22:1856-64
Blackler, Ryan J; Evans, Dylan W; Smith, David F et al. (2016) Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific manner†. Glycobiology 26:181-92

Showing the most recent 10 out of 162 publications